FDA panel approves outcomes claim for Vytorin

The FDA advisory panel reviewing a new indication for Merck's ($MRK) cholesterol fighter Vytorin gave the drug a nod for preventing cardiovascular problems in patients with kidney disease, but voted against the indication for kidney patients on dialysis. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.